AR and prostate cancer: In prostate cancer, the loss of CHD1, a chromatin remodeler, disrupts chromatin integrity, leading to increased transcriptional plasticity and resistance to AR-targeted therapies.81 DNA methylation is another critical epigenetic mechanism driving lineage plasticity.